Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Return on Sales for 6 consecutive years, with 1.15% as the latest value for Q3 2025.

  • For Q3 2025, Return on Sales changed N/A year-over-year to 1.15%; the TTM value through Sep 2025 reached 1.45%, changed N/A, while the annual FY2022 figure was 86.98%, 7297.0% down from the prior year.
  • Return on Sales hit 1.15% in Q3 2025 for Cyclerion Therapeutics, up from 17.98% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.15% in Q3 2025 and bottomed at 216.05% in Q1 2021.
  • Average Return on Sales over 4 years is 44.22%, with a median of 28.56% recorded in 2021.
  • Year-over-year, Return on Sales crashed -19610bps in 2021 and then surged 19779bps in 2022.
  • Cyclerion Therapeutics' Return on Sales stood at 26.9% in 2021, then dropped by -29bps to 34.81% in 2022, then crashed by -146bps to 85.56% in 2023, then soared by 99bps to 1.15% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 1.15%, 17.98%, and 17.99% for Q3 2025, Q2 2025, and Q1 2025 respectively.